Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H20N2S.C4H4O4 |
Molecular Weight | 400.491 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
Stereo Comments | C17H20N2S |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CC(CN1C2=C(SC3=C1C=CC=C3)C=CC=C2)N(C)C
InChI
InChIKey=JSYGKADGBBTFIQ-BTJKTKAUSA-N
InChI=1S/C17H20N2S.C4H4O4/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;5-3(6)1-2-4(7)8/h4-11,13H,12H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12657913 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Preventing | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
48.26 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.04 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
180.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
627.13 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
361 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
256 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disc. AE: Sinus tachycardia, Consciousness decreased... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Page: p.242Consciousness decreased Agitation Confusion Disorientation Visual hallucinations Delirium |
160 mg single, intramuscular Highest studied dose Dose: 160 mg Route: intramuscular Route: single Dose: 160 mg Sources: Page: p.199 |
healthy, 21.4±1.7 n = 6 Health Status: healthy Age Group: 21.4±1.7 Sex: M+F Population Size: 6 Sources: Page: p.199 |
|
120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: Page: p.199 |
healthy, 22.7±2.31 n = 10 Health Status: healthy Age Group: 22.7±2.31 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
80 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 80 mg, 1 times / day Route: intramuscular Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.199 |
healthy, 24.2±1.17 n = 10 Health Status: healthy Age Group: 24.2±1.17 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Disc. AE: Respiratory depression, Irritation skin... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.1Irritation skin (severe) Pain Thrombophlebitis |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.2, 3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Confusion | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Consciousness decreased | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Delirium | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disorientation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Sinus tachycardia | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Visual hallucinations | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Pain | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Thrombophlebitis | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Irritation skin | severe Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 32 uM] | ||||
yes [Inhibition 88 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Role of central histaminergic system in lorazepam withdrawal syndrome in rats. | 2001 Apr |
|
Angle closure risk from proprietary medicines. | 2001 Apr |
|
A new goldfish model to evaluate pharmacokinetic and pharmacodynamic effects of drugs used for motion sickness in different gravity loads. | 2001 Aug-Nov |
|
[Work time distribution in night shift: are clinics facing a adjustment boom?]. | 2001 Jul |
|
Spectrofluorometric determination of 2- and 10-disubstituted phenothiazines. | 2001 Jul-Aug |
|
Mechanistic appraisal of the charge-transfer complexes of promethazine with chloranil: a modelling approach. | 2001 Jun |
|
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. | 2001 May |
|
Adverse reactions related to phenergan. | 2001 May-Jun |
|
Extractive-spectrophotometric determination of some 2- and 10-disubstituted phenothiazines with dipicrylamine. | 2001 May-Jun |
|
Standard treatment: the role of antihistamines. | 2001 Nov |
|
Quantitation of promethazine and metabolites in urine samples using on-line solid-phase extraction and column-switching. | 2001 Nov 5 |
|
Amphotericin B-induced seizures in a patient with AIDS. | 2001 Sep |
|
Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease. | 2001 Sep |
|
Enantioseparation of phenothiazines in capillary zone electrophoresis using cyclodextrins as chiral selectors. | 2001 Sep 28 |
|
Comparing the safety, efficacy and recovery of intranasal midazolam vs. oral chloral hydrate and promethazine. | 2001 Sep-Oct |
|
[The activity of enzymes and free radical oxidation in acute and chronic fetal hypoxia in general anesthesia during cesarean section]. | 2002 |
|
[Suicidal attempts with old (currently unused) drug]. | 2002 |
|
Antihistamine antinociception is mediated by Gi-protein activation. | 2002 |
|
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. | 2002 |
|
Immunoassay screening of lysergic acid diethylamide (LSD) and its confirmation by HPLC and fluorescence detection following LSD ImmunElute extraction. | 2002 Apr |
|
A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. | 2002 Apr |
|
Toxicity of ethacrynic acid in isolated rat hepatocytes. | 2002 Apr |
|
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. | 2002 Feb |
|
Low-molecular-weight chiral cation exchangers: novel chiral stationary phases and their application for enantioseparation of chiral bases by nonaqueous capillary electrochromatography. | 2002 Feb |
|
[A case of fluvoxamine overdose]. | 2002 Jan |
|
Extractive-spectrophotometric determination of some phenothiazines with dipicrylamine and picric acid. | 2002 Jan 1 |
|
Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. | 2002 Jan 7 |
|
Recovery, enrichment and selectivity in liquid-phase microextraction comparison with conventional liquid-liquid extraction. | 2002 Jul 19 |
|
Fibromyositis after intramuscular pentazocine abuse. | 2002 Jul-Sep |
|
Central effects of cinnarizine: restricted use in aircrew. | 2002 Jun |
|
Next generation antihistamines: therapeutic rationale, accomplishments and advances. | 2002 Jun |
|
Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. | 2002 Jun 19 |
|
Cesarean delivery: a randomized trial of epidural analgesia versus intravenous meperidine analgesia during labor in nulliparous women. | 2002 Mar |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
|
Interaction of protonated anticancer thiazines with water-insoluble phospholipids and antineoplastic agents. | 2002 Mar-Apr |
|
Anxiolytic premedication reduces preoperative anxiety and pain during oocyte retrieval. A randomized double-blinded placebo-controlled trial. | 2002 May |
|
Effect of some psychotropic drugs on luminol-dependent chemiluminescence induced by O2-, *OH, HOCl. | 2002 Nov-Dec |
|
Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. | 2002 Oct |
|
Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine. | 2002 Oct |
|
Acute allergic reaction following contact with a spider. | 2002 Oct |
|
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. | 2002 Oct 16 |
|
[Landau-Kleffner and autistic regression: the importance of differential diagnosis]. | 2002 Sep |
|
A case of homicide by lethal injection with lidocaine. | 2002 Sep |
|
A comparative evaluation of oral midazolam with other sedatives as premedication in pediatric dentistry. | 2002 Winter |
|
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. | 2003 Apr |
|
Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. | 2003 Apr |
|
Inactivation of cholinesterase induced by chlorpromazine cation radicals. | 2003 Feb |
|
Interaction of carbamazepine and promethazine in rabbits. | 2003 Jan |
|
Phenothiazine radicals inactivate Trypanosoma cruzi dihydrolipoamide dehydrogenase: enzyme protection by radical scavengers. | 2003 Mar |
|
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants. | 2003 May |
Sample Use Guides
Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature.
Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered.
Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated.
For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary.
Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation.
Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep.
For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug.
Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
27059-74-1
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY | |||
|
9764B60L6Y
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY | |||
|
6441486
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY | |||
|
SUB130781
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY | |||
|
248-197-4
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY | |||
|
100000156759
Created by
admin on Sat Dec 16 10:28:49 GMT 2023 , Edited by admin on Sat Dec 16 10:28:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD